Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating the combination of IBI310 and Sintilimab as first-line therapy for hepatocellular carcinoma and is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2, Phase 3 | Status: RECRUITING